Solid Tumors - Healing Genes

Solid Tumors

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

TCR-engineered T Cells in Solid Tumors (ACTengine)

Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Relapsed and/or Refractory Solid Tumors (ACTengine IMA203-101)

Phase 1


MD Anderson Cancer Center researchers seek patients with solid tumors to trial a new gene-modified stem cell transplant (autologous) which uses a new technology to genetically modify their immune T-cells to attack their tumor. This investigational immunotherapy is customized to the patient.

The treatment will require leukapheresis to collect the T-cells for gene modification, chemotherapy before they are re-infused, and proleukin drugs to help the cells grow. Follow up, including lab and imaging assessments, may continue for up to 12 months.

Line __:


  • Be 18 years of age or older
  • Have pathologically confirmed advanced and/or metastatic solid tumor
  • Have life expectancy more than 3 months

Line __:


  1. Screening to confirm acceptance to the study.
  2. Leukapheresis to collect the patient’s own stem cells, which will be gene-modified in the lab (no treatment during that period) to target cancer cells.
  3. Admission to the study center and a course of chemotherapy.
  4. Infusion of the gene-modified stem cells, followed by aldesleukin/proleukin to promote their growth.
  5. Follow up, including lab and imaging assessments, may continue for up to 12 months.



The study site is at the University of Texas MD Anderson Cancer Center in Houston, TX Map.


Jorge Rivas, M.D.  |  346-204-5350  |  [email protected]



Immatics US, Inc.

M.D. Anderson Cancer Center


Or go online:

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader